About Vascugel®

Vascugel®

Vascugel®, a novel, biologically active therapy developed using tissue-engineered allogeneic endothelium, is under investigation for enhancing blood vessel repair and promoting vascular health.

Vascugel® couples a well-characterized polymer matrix with allogeneic endothelial cells to deliver growth regulatory compounds directly to the site of vascular injury, promoting a natural healing process and preventing excessive scar tissue formation, inflammation and thrombosis. The biological activity of Vascugel® allows its application in a broad array of vascular procedures where poor medical outcomes result from intimal hyperplasia, stenosis and loss of patency at the site of intervention.

Two Phase 2 clinical studies for Vascugel® as a concurrent therapy with arteriovenous access procedures in patients with end-stage renal disease have been successfully completed. In these studies, patients treated with Vascugel® had fewer interventions, thrombotic events and complications than placebo-treated patients.

In May 2009, Vascugel® received an Orphan Drug designation from the U.S. Food and Drug Administration for the prevention of arteriovenous fistula or arteriovenous graft failure in patients with end-stage renal disease. 

Vascugel® Informational Video